🩺What is Nasal Polyposis?
The SNOT-22 questionnaire has been developed and validated over more than two decades of rhinology research, evolving from the original SNOT-16 (1999) and SNOT-20 (2004) versions. The current 22-item version was recommended by the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) as the standard patient-reported outcome measure for CRS clinical trials. Each item is rated on a 0-5 Likert scale (0 = no problem, 5 = problem as bad as it can be), yielding a total score from 0 to 110. Higher scores indicate greater symptom severity and quality of life impairment.
📊Clinical Assessment & Risk Scoring
Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Nasal Polyposis:
SNOT-22 — Sino-Nasal Outcome Test
The SNOT-22 (Sino-Nasal Outcome Test-22) is a validated 22-item patient-reported outcome measure used to evaluate chronic rhinosinusitis (CRS) symptom severity and quality of life impact. It covers nasal, paranasal, sleep, and emotional domains.
🧬Diagnostic Logic & Scoring Breakdown
The SNOT-22 covers five domains: nasal symptoms (need to blow nose, sneezing, runny nose, nasal obstruction, loss of smell/taste, thick nasal discharge), paranasal symptoms (cough, postnasal discharge, thick discharge from nose, ear fullness, dizziness, ear pain, facial pain/pressure), sleep dysfunction (difficulty falling asleep, waking up at night, lack of good night sleep, waking up tired, fatigue), emotional dysfunction (frustration/restlessness/irritability, sadness, feeling embarrassed), and productivity impact (reduced productivity, reduced concentration). Each item is scored from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of all 22 responses. A score of ≤10 suggests mild symptoms unlikely due to CRS. Scores 11-30 suggest mild-to-moderate impact. Scores 31-50 indicate moderate-to-severe impact. Scores 51-70 indicate severe impact. Scores >70 indicate very severe impact with major quality of life impairment.
📢Clinical Significance & Implications
The SNOT-22 is the most widely used patient-reported outcome measure in rhinology worldwide. Its psychometric properties have been extensively validated, demonstrating high test-retest reliability (ICC 0.94), excellent internal consistency (Cronbach's alpha 0.91), and strong construct validity against SF-36 and other quality of life measures. The minimal clinically important difference (MCID) for SNOT-22 is 8.9 points, meaning that a change of 9 or more points represents a meaningful clinical improvement. The SNOT-22 is the recommended outcome measure by EPOS (European Position Paper on Rhinosinusitis) and is used as the primary endpoint in most CRS clinical trials, including the landmark EMBRACE trial evaluating mepolizumab in nasal polyps, and multiple studies evaluating biologic therapies (dupilumab, omalizumab, benralizumab) for CRSwNP. The questionnaire's five domains allow clinicians to identify which symptom clusters are most problematic for individual patients (nasal, paranasal, sleep, emotional, productivity), enabling targeted therapy. A pre-treatment SNOT-22 score >30 is often used as a threshold for considering surgical intervention, and post-treatment improvement of >MCID (>9 points) indicates treatment success.
💡 Clinical Assessment Scenario Example
A 45-year-old male with chronic rhinosinusitis for 3 years completes the SNOT-22. His responses yield a total score of 64. Interpretation: Severe CRS strongly impacting daily life. Recommendation: Full medical therapy with intranasal corticosteroids, saline irrigations, and consideration of CT sinus imaging and ENT specialist referral.
💊Common Medications & Interventions
The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Nasal Polyposis:
⚠️Clinical Assessment Pitfalls
❌ Mistake: Using SNOT-22 as a diagnostic tool for CRS
✅ Correction: SNOT-22 is a symptom severity and quality of life outcome measure, not a diagnostic tool. CRS diagnosis requires clinical criteria (symptoms ≥12 weeks, endoscopic/imaging findings) per EPOS or AAO-HNS guidelines. SNOT-22 should be used to assess symptom burden and treatment response, not to establish diagnosis.
🚑When to Seek Medical Attention
This reference supports clinical assessment of Nasal Polyposis; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.
❓Frequently Asked Questions
Q: How is SNOT-22 different from SNOT-20?
SNOT-22 adds two items to the original SNOT-20: (1) nasal obstruction/congestion and (2) loss of sense of smell or taste. These two nasal symptoms are particularly important in CRS and nasal polyposis, making SNOT-22 more comprehensive and clinically relevant. EPOS 2020 and 2024 both recommend SNOT-22 as the preferred outcome measure over SNOT-20.
Q: What is the minimal clinically important difference (MCID) for SNOT-22?
The MCID for SNOT-22 is 8.9 points. A change of 9 or more points represents a clinically meaningful improvement or deterioration. This threshold is used to define treatment success in clinical trials and surgical outcomes research.
📚Evidence-Based References
Medically Reviewed By
Dr. Mahmoud El-Sayed
MD, ENT | Otorhinolaryngology
Dr. Mahmoud El-Sayed is a consultant otorhinolaryngologist with over 15 years of experience in clinical ENT practice.